title: Plasma calcitonin, IGF-I levels and vertebral bone mineral density in hyperprolactinemic women during bromocriptine treatment.
abstract: Hyperprolactinemia is associated with decreased bone mineral density, which may be caused by the hypogonadism and hypoestrogenicity noticed in patients with hyperprolactinemia. Since calcitonin inhibits the bone resorption, and insulin-like growth factor I (IGF-I) has important anabolic effects on the skeleton, lack of one or both peptides may contribute to the development of osteopenia. We therefore measured the plasma calcitonin and IGF-I levels in nine women with hyperprolactinemia caused by a prolactin-producing pituitary tumor. The calcium-stimulated C-cell reactivity was studied by measuring calcitonin in plasma during a calcium clamp before and after normalization of serum prolactin during treatment with bromocriptine. Basal CT levels were measurable but lower than in healthy controls. Basal IGF-I levels and calcium-stimulated plasma calcitonin were normal in the hyperprolactinemic state and similar to the calcitonin and IGF-I levels during bromocriptine treatment. The serum prolactin levels decreased (p < 0.001) and the serum estradiol levels increased (p < 0.001). The bone mineral density of the lumbar spine increased significantly during treatment. Thus, basal plasma CT levels are slightly reduced in hyperprolactinemic women. However, the reversible osteopenia in hyperprolactinemic women is less likely to be caused by inhibited IGF-I secretion or by deficient CT levels since the CT response to calcium is normal. In addition, bromocriptine treatment with normalization of prolactin levels is beneficial for the bone mineral content in this condition.
authors.affiliation: Department of Endocrinology, Karolinska Hospital and Institute, Stockholm, Sweden.
authors.forename: O
authors.initials: O
authors.lastname: Tørring
authors.forename: B
authors.initials: B
authors.lastname: Isberg
authors.forename: H E
authors.initials: HE
authors.lastname: Sjöberg
authors.forename: E
authors.initials: E
authors.lastname: Bucht
authors.forename: A L
authors.initials: AL
authors.lastname: Hulting
mesh_terms: D000328:Adult; D015519:Bone Density / Q000187:drug effects*; D001971:Bromocriptine / Q000494:pharmacology / Q000627:therapeutic use*; D002116:Calcitonin / Q000097:blood*; D002118:Calcium / Q000097:blood; D004958:Estradiol / Q000097:blood; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D008159:Lumbar Vertebrae / Q000737:chemistry / Q000187:drug effects; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000150:complications; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000150:complications; D011863:Radioimmunoassay; D013997:Time Factors
chemical_list: D001971:Bromocriptine; D004958:Estradiol; D007334:Insulin-Like Growth Factor I; D011388:Prolactin; D013006:Growth Hormone; D002116:Calcitonin; D002118:Calcium